tirzepatide houma for Non-alcoholic Fatty Liver Disease (NAFLD) in Houma, Louisiana glp-1 therapy houma Compounded GLP-1

We report the case of a 39-year-old man with no significant comorbidities who developed life-threatening hypoglycemia, profound electrolyte abnormalities, pancytopenia, and aspiration pneumonia following unsupervised rapid dose escalation of tirzepatide used for weight loss

A groundbreaking study suggests a 33% reduction in suicidal thoughts among obese adolescents using semaglutide-based treatments

Discover the evidence on rectal bleeding with semaglutide, when to seek urgent medical help, and other possible causes in this expert UK medical guide.

Headline results from OASIS 1 - a phase 3a 68-week, efficacy and safety trial comparing once-daily oral semaglutide 50 mg for weight management to placebo in 667 adults with obesity or overweight with one or more comorbidities have revealed the trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with oral semaglutide 50mg versus placebo.When evaluating the effects of treatment if all people adhered to treatment from a mean baseli